$Volumetric Response of Limited Brain Metastatic Disease to Focal Hypofractionated Radiation Therapy$
Código QR

Volumetric Response of Limited Brain Metastatic Disease to Focal Hypofractionated Radiation Therapy

<i>Background</i>: This is a retrospective study aimed at assessing the volumetric response, morbidity and failure rates of hypofractionated radiation therapy (HFRT) for definitive focal management of limited brain metastasis. <i>Methods</i>: Patients managed with HFRT for un...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Asanka R. Wijetunga, Dasantha T. Jayamanne, Jessica Adams, Michael F. Back
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	brain metastasis hypofractionated radiotherapy volume response radiation necrosis overall survival Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571
Acceso en línea:	https://doaj.org/article/7df870a3861f420082e51bd8b2e5878e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7df870a3861f420082e51bd8b2e5878e
record_format	dspace
spelling	oai:doaj.org-article:7df870a3861f420082e51bd8b2e5878e2021-11-25T16:57:46ZVolumetric Response of Limited Brain Metastatic Disease to Focal Hypofractionated Radiation Therapy10.3390/brainsci111114572076-3425https://doaj.org/article/7df870a3861f420082e51bd8b2e5878e2021-11-01T00:00:00Zhttps://www.mdpi.com/2076-3425/11/11/1457https://doaj.org/toc/2076-3425<i>Background</i>: This is a retrospective study aimed at assessing the volumetric response, morbidity and failure rates of hypofractionated radiation therapy (HFRT) for definitive focal management of limited brain metastasis. <i>Methods</i>: Patients managed with HFRT for unresected limited metastatic (≤10 lesions) brain disease were entered into an ethics-approved database. Included patients had been deemed unsuitable for surgical resection, and lesions managed with prior radiation therapy were excluded. HFRT was delivered using IMRT or VMAT with 25 Gy or 30 Gy in five fractions. Individual lesions had volumetric assessment performed at three timepoints. The primary endpoint was the change of volume from baseline (GTV0) to one month post-HFRT (GTV1) and to seven months post-HFRT (GTV7). Secondary endpoints were local failure, survival and rates of radiation necrosis. <i>Results</i>: One hundred and twenty-four patients with 233 lesions were managed with HFRT. Median follow-up was 23.5 months with 32 (25.8%) patients alive at censure. Median overall survival was 7.3 months with 36.3% survival at 12 months. Superior survival was predicted by smaller GTV0 (<i>p</i> = 0.003) and increased percentage of volumetric response (<i>p</i> < 0.001). Systemic therapy was delivered to 81.5% of patients. At one month post-HFRT, 206 metastases (88.4%) were available for assessment and at seven months post-HFRT, 118 metastases (50.6%) were available. Median metastasis volume at GTV0 was 1.6 cm<sup>3</sup> (range: 0.1–19.1). At GTV1 and GTV7, this reduced to 0.7 cm<sup>3</sup> (<i>p</i> < 0.001) and 0.3 cm<sup>3</sup> (<i>p</i> < 0.001), respectively, correlating to percentage reductions of 54.9% and 83.3%. No significant predictors of volumetric response following HFRT were identified. Local failure was identified in 4.3% of lesions and radiation necrosis in 3.9%. <i>Conclusion</i>: HFRT is an effective therapy for limited metastatic disease in the brain to maximise initial volumetric response whilst minimising toxicity.Asanka R. WijetungaDasantha T. JayamanneJessica AdamsMichael F. BackMDPI AGarticlebrain metastasishypofractionated radiotherapyvolume responseradiation necrosisoverall survivalNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571ENBrain Sciences, Vol 11, Iss 1457, p 1457 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	brain metastasis hypofractionated radiotherapy volume response radiation necrosis overall survival Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571
spellingShingle	brain metastasis hypofractionated radiotherapy volume response radiation necrosis overall survival Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Asanka R. Wijetunga Dasantha T. Jayamanne Jessica Adams Michael F. Back Volumetric Response of Limited Brain Metastatic Disease to Focal Hypofractionated Radiation Therapy
description	<i>Background</i>: This is a retrospective study aimed at assessing the volumetric response, morbidity and failure rates of hypofractionated radiation therapy (HFRT) for definitive focal management of limited brain metastasis. <i>Methods</i>: Patients managed with HFRT for unresected limited metastatic (≤10 lesions) brain disease were entered into an ethics-approved database. Included patients had been deemed unsuitable for surgical resection, and lesions managed with prior radiation therapy were excluded. HFRT was delivered using IMRT or VMAT with 25 Gy or 30 Gy in five fractions. Individual lesions had volumetric assessment performed at three timepoints. The primary endpoint was the change of volume from baseline (GTV0) to one month post-HFRT (GTV1) and to seven months post-HFRT (GTV7). Secondary endpoints were local failure, survival and rates of radiation necrosis. <i>Results</i>: One hundred and twenty-four patients with 233 lesions were managed with HFRT. Median follow-up was 23.5 months with 32 (25.8%) patients alive at censure. Median overall survival was 7.3 months with 36.3% survival at 12 months. Superior survival was predicted by smaller GTV0 (<i>p</i> = 0.003) and increased percentage of volumetric response (<i>p</i> < 0.001). Systemic therapy was delivered to 81.5% of patients. At one month post-HFRT, 206 metastases (88.4%) were available for assessment and at seven months post-HFRT, 118 metastases (50.6%) were available. Median metastasis volume at GTV0 was 1.6 cm<sup>3</sup> (range: 0.1–19.1). At GTV1 and GTV7, this reduced to 0.7 cm<sup>3</sup> (<i>p</i> < 0.001) and 0.3 cm<sup>3</sup> (<i>p</i> < 0.001), respectively, correlating to percentage reductions of 54.9% and 83.3%. No significant predictors of volumetric response following HFRT were identified. Local failure was identified in 4.3% of lesions and radiation necrosis in 3.9%. <i>Conclusion</i>: HFRT is an effective therapy for limited metastatic disease in the brain to maximise initial volumetric response whilst minimising toxicity.
format	article
author	Asanka R. Wijetunga Dasantha T. Jayamanne Jessica Adams Michael F. Back
author_facet	Asanka R. Wijetunga Dasantha T. Jayamanne Jessica Adams Michael F. Back
author_sort	Asanka R. Wijetunga
title	Volumetric Response of Limited Brain Metastatic Disease to Focal Hypofractionated Radiation Therapy
title_short	Volumetric Response of Limited Brain Metastatic Disease to Focal Hypofractionated Radiation Therapy
title_full	Volumetric Response of Limited Brain Metastatic Disease to Focal Hypofractionated Radiation Therapy
title_fullStr	Volumetric Response of Limited Brain Metastatic Disease to Focal Hypofractionated Radiation Therapy
title_full_unstemmed	Volumetric Response of Limited Brain Metastatic Disease to Focal Hypofractionated Radiation Therapy
title_sort	volumetric response of limited brain metastatic disease to focal hypofractionated radiation therapy
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/7df870a3861f420082e51bd8b2e5878e
work_keys_str_mv	AT asankarwijetunga volumetricresponseoflimitedbrainmetastaticdiseasetofocalhypofractionatedradiationtherapy AT dasanthatjayamanne volumetricresponseoflimitedbrainmetastaticdiseasetofocalhypofractionatedradiationtherapy AT jessicaadams volumetricresponseoflimitedbrainmetastaticdiseasetofocalhypofractionatedradiationtherapy AT michaelfback volumetricresponseoflimitedbrainmetastaticdiseasetofocalhypofractionatedradiationtherapy
_version_	1718412846337884160

Volumetric Response of Limited Brain Metastatic Disease to Focal Hypofractionated Radiation Therapy

Ejemplares similares